Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | EBV-LMP2-specific TCR for EBV associated malignancies

Wesley Huisman • 3 Sep 2020
EBMT 2020
Lymphoma

Wesley Huisman, MSc, Leiden University Medical Center, Leiden, The Netherlands, discusses his abstract on the development of the first functional human leukocyte antigen (HLA) 01-restricted Epstein-Barr virus latent membrane protein 2 specific (EBV-LMP2-specific) T-cell receptors (TCR) for TCR gene therapies for EBV associated malignancies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Wesley Huisman

5:54
HLA cross-reactivity by virus specific T-cells
Wesley Huisman • 3 Sep 2020

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals